|Systematic (IUPAC) name|
|(what is this?)|
Canbisol (Nabidrox), is a synthetic cannabinoid derivative that is the dimethylheptyl homologue of 9-nor-9β-hydroxyhexahydrocannabinol (HHC). It is a potent agonist at both the CB1 and CB2 receptors, with a binding affinity of 0.1nM at CB1 and 0.2nM at CB2. It is mainly used in scientific research, in receptor binding studies to determine the structure and function of the cannabinoid receptors, but has been made illegal in some countries due to its possible abuse potential as a cannabinomimetic drug.
- Rhee MH et al. (September 1997). "Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase". Journal of Medicinal Chemistry 40 (20): 3228–33. doi:10.1021/jm970126f. PMID 9379442.
- Rhee MH et al. (December 2000). "Functional role of tryptophan residues in the fourth transmembrane domain of the CB(2) cannabinoid receptor". Journal of Neurochemistry 75 (6): 2485–91. PMID 11080201.
- Rhee MH (September 2002). "Functional role of serine residues of transmembrane dopamin VII in signal transduction of CB2 cannabinoid receptor". Journal of Veterinary Science 3 (3): 185–91. PMID 12514330.
- Zhang R et al. (July 2005). "Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template". Molecular Pharmacology 68 (1): 69–83. doi:10.1124/mol.104.007823. PMID 15840841.
- The Misuse of Drugs Act 1971 (Amendment) Order 2009
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|